N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus  by Dey, Antu K. et al.
Available online at www.sciencedirect.com
8) 187–200
www.elsevier.com/locate/yviroVirology 372 (200N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric
envelope glycoproteins on the virus
Antu K. Dey a, Kathryn B. David a, Neelanjana Ray b, Thomas J. Ketas a, Per J. Klasse a,
Robert W. Doms b, John P. Moore a,⁎
a Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, Room W-805, New York, NY 10065, USA
b Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
Received 28 August 2007; returned to author for revision 1 October 2007; accepted 16 October 2007
Available online 26 November 2007Abstract
The native, functional HIV-1 envelope glycoprotein (Env) complex is a trimer of two non-covalently associated subunits: the gp120 surface
glycoprotein and the gp41 transmembrane glycoprotein. However, various non-functional forms of Env are present on virus particles and HIV-1-
infected cells, some of which probably arise as the native complex decays. The aberrant forms include gp120–gp41monomers and oligomers, as well
as gp41 subunits from which gp120 has dissociated. The presence of non-functional Env creates binding sites for antibodies that do not recognize
native Env complexes and that are, therefore, non-neutralizing. Non-native Env forms (monomers, dimers, tetramers and aggregates) can also arise
when soluble gp140 proteins, lacking the cytoplasmic and transmembrane domains of gp41, are expressed for vaccine studies. We recently identified
five amino acids in the gp41 N-terminal region (I535, Q543, S553, K567 and R588) that promote gp140 trimerization. We have now studied their
influence on the function and antigenic properties of JR-FL Env expressed on the surfaces of pseudoviruses and Env-transfected cells. The 5
substitutions in gp41 reduce the expression of non-trimeric gp160s, without affecting trimer levels. Pseudovirions bearing the mutant Env are fully
infectious with similar kinetics of Env-mediated fusion. Various non-neutralizing antibodies bind less strongly to the Env mutant, but neutralizing
antibody binding is unaffected. Hence the gp41 substitutions do not adversely affect Env structure, supporting their use for making new Env-based
vaccines. The mutant Env might also help in studies intended to correlate antibody binding to virus neutralization. Of note is that the 5 residues are
much more frequent, individually or collectively, in viruses from subtypes other than B.
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The HIV-1 envelope glycoprotein (Env) complex is present
on the virus surface as a labile structure comprising non-
covalently-associated surface gp120 and transmembrane gp41
glycoprotein subunits. To mediate HIV-1 entry into target cells,
the Env complex undergoes a series of receptor-triggered
conformational changes that culminate in virus–cell fusion
(Jones et al., 1998; Melikyan et al., 2000; Sattentau and Moore,
1991; Sullivan et al., 1998; Trkola et al., 1996a; Wu et al., 1996;⁎ Corresponding author. Fax: +1 212 746 8340.
E-mail address: jpm2003@med.cornell.edu (J.P. Moore).
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doi:10.1016/j.virol.2007.10.018Wyatt and Sodroski, 1998). The instability of the Env
complexes is probably essential to permit these conformational
changes to proceed efficiently during the fusion process, but it
does present a challenge for designers of Env-based vaccines,
particularly if the goal is to make immunogens that mimic the
native Env structure. Thus, gp120 rapidly dissociates from gp41
when soluble forms of gp140 proteins are expressed, and
trimeric gp140 proteins can degrade into dimers and monomers,
or associate into tetramers (dimers of dimers) and aggregates
(Earl et al., 1994; Schulke et al., 2002; Staropoli et al., 2000).
Similarly, monomeric and oligomeric gp120–gp41 structures
are present on cells that express Env proteins, as are gp41
“stumps” from which gp120 has been shed and uncleaved
proteins that have evaded the host cell proteases that process the
gp160 precursor protein (Herrera et al., 2005; Kuznetsov et al.,
188 A.K. Dey et al. / Virology 372 (2008) 187–2002003; Moore et al., 2006; Thomas et al., 1991; Wyatt and
Sodroski, 1998; Zhu et al., 2003).
We have been attempting to overcome the structural
instability of the native Env complex, or soluble forms thereof,
by introducing various amino acid sequence changes that are
designed to stabilize inter-subunit interactions between gp120
and gp41 or between the gp41 components of a trimer (Binley
et al., 2000; Sanders et al., 2002). Thus we introduced a
disulfide bond between gp120 and gp41, together with an
additional change in gp41 that promotes trimer stability after
gp120 and gp41 are cleaved into separate subunits during Env
processing (Binley et al., 2000; Sanders et al., 2002). The
resulting gp140 proteins are designated SOSIP. Additional
changes at the cleavage site between gp120 and gp41 promote
proteolytic processing (Binley et al., 2002). Recently, we have
shown that five amino acid changes in the highly conserved
Leucine-zipper (LZ) like motif near the N-terminus of gp41
contribute to trimer stability, by reducing the prevalence of
monomeric, dimeric or aggregated forms of gp140 (Dey et al.,
2007). The resulting reduction in the qualitative heterogeneity
of Env may be useful for the production of vaccines that attempt
to mimic native trimers.
The beneficial effect of the amino acid changes in gp41
could, however, be countered if they substantially compromise
Env structure by creating a non-native configuration. Even
though the sequence changes are in gp41, there is ample
precedent for amino acid variation in this subunit affecting the
conformation of gp120 and the overall topology and function of
the entire Env complex. For example, mutations in or near the
LZ region of gp41 are known to affect the binding and action of
anti-gp120 antibodies, creating neutralization-resistant viruses
(Back et al., 1993; Klasse et al., 1993; Park et al., 1998, 2000;
Park and Quinnan, 1999; Thali et al., 1994). Other changes in
gp41 affect the sensitivity of HIV-1 to small molecules that bind
near the CD4-binding site on gp120 (Guo et al., 2003; Lin et al.,
2003). We have therefore studied whether the five changes in
gp41 that promote the stability of gp140 trimers affect Env
expression, antigenic structure, neutralization sensitivity and
fusion function when made in the context of fusion-competent
proteins from HIV-1 JR-FL. We observed that the altered Env
proteins do retain their function, with little or no change in the
rate of Env-mediated fusion.Table 1
The table lists the prevalence (expressed as a percentage) of the five trimer-promotin
gp41 sequences from viruses of subtypes A, B, C, D, and from subtypes F+G+H+J
available to warrant a separate analysis)
Subtypes and CRFs Number of isolates (n) I535 Q543
A 78 72 94
B 200 26 59
C 201 87 95
D 54 4 89
F–H, J, K 35 91 97
P values (subtype B vs. rest): ≪0.001 ≪0.001
The sequences were obtained from the Los Alamos HIV-1 Sequence Database. Note t
subtype A as the “subtype E” env gene is actually from subtype A. The comparative
highlighted in grey. The statistical significance (P value) of the prevalence of the five
subtypes is calculated using Fisher's Exact Test.We also found that the five sequence changes reduced the
proportion of aberrant, non-trimeric Env forms present on the
surfaces of virions. These non-functional Env proteins serve as
targets for the binding of non-neutralizing antibodies, compli-
cating any analysis of the relationships between antibody
binding and virus neutralization (Broder et al., 1994; Cavacini
and Posner, 2004; Fouts et al., 1997, 1998; Herrera et al., 2003;
Moore et al., 1995, 2006; Poignard et al., 2003; Sattentau and
Moore, 1995; York et al., 2001). Accordingly, the binding of
various non-neutralizing antibodies to virions and Env-expres-
sing cells was reduced for the gp41 mutant compared to wild-
type JR-FL, without adversely affecting the binding of
neutralizing antibodies. The use of the gp41-mutated form of
Env may therefore simplify future analyses of antibody binding
and neutralization.
Results
We recently reported that five amino acids, I535, Q543,
S553, K567 and R588, located near the N-terminus of HIV-1
gp41 are associated with the formation and/or stability of
soluble, trimeric gp140 proteins based on the subtype A strain
KNH1144. Moreover, introducing these residues into subtype B
gp140 proteins with different amino acids at the same positions
had a beneficial impact on trimer stability (Dey et al., 2007). Of
the 5 residues, Q543, S553 and K567 have the greatest effect
when introduced in combination, with I535 and R588 perhaps
making an additional, minor contribution (Dey et al., 2007). An
analysis of gp41 sequences in the Los Alamos HIV-1 Sequence
Database shows that I535, Q543, S553 and K567, but not R588,
were individually and collectively far more prevalent in subtype
A viruses than in ones from subtype B (Table 1). Their
frequency in subtype C viruses was similar to subtype A, with
the notable exception of K567, which was completely absent.
Subtype D frequencies were similar, but not identical, to
subtype B. Too few sequences from the individual subtypes F,
G, H, J and K are available to warrant a similar analysis, but
treating these “minor” subtypes en masse showed that their
gp41 residue frequencies were more similar to subtype A than
subtype B. Overall, in respect to these 5 positions in gp41,
subtype B viruses stand out as being different from the other
subtypes’ (see Table 1 for statistical significance).g amino acids (I535, Q543, S553, K567 and R588), singly or in combination, in
+K treated collectively (too few sequences from subtypes F, G, H, J and K were
S553 K567 R588 All five amino acids
90 81 33
10 0.5 35 0%
90 0 12 0%
4 0 22 0%
69 86 6 3%
≪0.001 ≪0.001 ≪0.001 b0.001
hat Env sequences from what was formerly called subtype E are included within
ly high collective prevalence of the five amino acids in subtype A sequences is
amino acids in subtype B viruses, singly or in combination, against the rest of the
Fig. 1. Effect of gp41 N-terminus substitutions on Env incorporation into
pseudovirions. The JR-FLWT and gp41 NT 1–5 mutant viruses were produced
by transfection of HEK 293T cells and pelleted from clarified supernatants. The
gp120, gp41 and p24 proteins were resolved by SDS-PAGE and analyzed by
Western blotting with the appropriate antibodies.
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incorporated into pseudovirions
In view of the potential general utility of the above gp41
mutation strategy for making stabilized gp140 trimers, we
sought to determine the effects of the 5 substitutions on Env
function when they were introduced into full-length, virion-
associated envelope glycoproteins. Because we had previously
studied their effect on gp140 trimer formation using the subtype
B isolate HIV-1 JR-FL, we used that virus for infectivity and
related studies. We therefore mutated the full-length, wild-type
(WT) JR-FL gp160 env gene (JR-FL WT) at the same 5
positions, to make the JR-FL gp41 NT 1–5 mutant. Env-
pseudotyped virions (pseudovirions) based on the WT and
mutant sequences were generated by co-transfecting HEK 293TFig. 2. Effect of gp41 N-terminal changes on the Env forms present on pseudovirions
gp41 NT 1–5 mutant Envs, were solubilized then analyzed under native conditions o
ARP3119. Env tetramers and dimers are highlighted with black arrows, trimers with a
forms present on the WT (black bars) and mutant (grey bars) pseudovirions. The d
independent experiments.cells with each individual full-length Env-encoding plasmid and
the pNL4-3.Luc.R−E− reporter plasmid (Connor et al., 1996).
Pseudovirions from the two preparations were pelleted by ultra-
centrifugation onto a 20% sucrose cushion and were found to
contain similar amounts of p24 antigen (107 pg/ml for WT,
112 pg/ml for NT 1–5 mutant). Their gp120 and gp41 contents
were then determined by SDS-PAGE and Western blotting
followed by densitometric analysis using ImageJ software
(Fig. 1). The normalized gp120:p24 ratios for the WT and
mutant viruses were 1 and 0.28 respectively; the corresponding
gp41:p24 ratios were 1 and 0.4. Thus, on average, the mutant
pseudovirions contain ∼3.5-fold less gp120 and 2.5-fold less
gp41 than the wild-type viruses per unit of particulate p24
antigen. Although similar values were obtained in four replicate
experiments, the imprecision of this type of analysis makes it
hard to judge whether the modestly greater reduction in the
gp120 content, compared to gp41, of the mutant viruses is
genuine or not. Additional analyses of gp120-shedding from the
WTand mutant viruses imply that the difference may not be real
(see below). Overall, we conclude that the mutants incorporate
and retain ∼30–40% of the total Env content of the wild-type
viruses.
We studied the Env content of the purified pseudovirions in
more detail by using BN-PAGE to assess the presence of
dimeric, trimeric and tetrameric Env forms (Fig. 2A). Consistent
with the gel analysis under denaturing conditions, the total Env
content of the mutants was∼2.5-fold lower than theWT viruses.
However, a densitometric analysis showed that this reduction
was entirely attributable to a decrease in the amounts of Env
tetramers and dimers present on the mutant particles (no
monomers were visible in either preparation); the trimer contents
of the two sets of virions were identical (Figs. 2A and B).
Overall, tetramers comprised 58% of the total Env content of the
WT viruses, trimers 34% and dimers 8%, whereas for the
mutants, the corresponding values were 35%, 62% and 3%.
We conclude that the majority of the Env proteins
incorporated into JR-FL WT pseudovirions produced in 293T
cells are non-trimeric, and that the presence of these aberrant
Env forms on the viral surface can be significantly (Pb0.05,. (A) Virions, normalized for p24 content and expressing either the JR-FLWTor
n a 4–12% Bis–Tris NuPAGE gel and Western blotted with the anti-gp120 MAb
grey arrow. (B) The histogram shows the relative proportions of the different Env
ensitometric data represents the mean±standard deviation of values from four
190 A.K. Dey et al. / Virology 372 (2008) 187–200Mann–Whitney U test, one-tailed) reduced by substituting five
amino acids in the N-terminal region of gp41.
Effect of gp41 substitutions on soluble CD4- and
temperature-induced gp120 shedding from pseudovirions
We noted above that there appeared to be a slight reduction
in the gp120 content of the mutant pseudoviruses, relative to
gp41, that could be attributable to an increase in shedding of
gp120 from functional or non-functional spikes. This scenario is
plausible, because changes in residues 528 to 562 have been
associated with a destabilization of the gp120–gp41 interaction
(Cao et al., 1993). To determine whether the WT and mutant
pseudoviruses behaved differently in this respect, we used
soluble CD4 (sCD4) and mild heat as inducers of gp120
shedding. To provide an external frame of reference, we also
studied the HxB2 isolate under the same conditions, as this type
of T-cell line-adapted virus is particularly prone to shedding its
gp120 content (Moore et al., 1992).
Neither the WT nor mutant JR-FL pseudoviruses shed
gp120 significantly in response to sCD4 concentrations up to
10 μg/ml, at either 4 °C or 37 °C, whereas HxB2 Env-bearing
pseudoviruses lost over half their gp120 content when treated
with 10 μg/ml of sCD4 at 37 °C (Fig. 3A). Moreover, the twoFig. 3. Effect of gp41 substitutions on soluble CD4- and temperature-induced gp120
gp41 NT 1–5 mutant Envs were incubated for 2 h with the sCD4 concentrations indic
temperatures indicated, in the absence of sCD4. In both experiments, the HxB2 Env
Env is expressed relative to that present on each virus in the absence of sCD4 at 4versions of JR-FL pseudoviruses behaved similarly in their
reactions to elevated temperatures, losing significant amounts
of gp120 only at 50 °C and 65 °C, but even then less so than
the HxB2 reference virus (Fig. 3B). Thus the five amino acid
substitutions in the N-terminal region of JR-FL gp41 do not
detectably destabilize the interactions between gp120 and
gp41.
Effect of gp41 substitutions on pseudovirion infectivity
Specific substitutions in the highly conserved N-terminal
heptad repeat 1 (HR1) region can impair the fusion function of
gp41 and the infectivity of mutant viruses (Cao et al., 1993;
Chen et al., 1993;Weng andWeiss, 1998).We therefore assessed
the infectivity of the WT and mutant JR-FL Env-pseudotyped
viruses (normalized for p24 content) in a single cycle assay using
U87.CD4.CCR5 target cells and a luciferase reporter gene read-
out 4 days post infection. The two viruses were equally
infectious (Fig. 4). Thus the five changes in the gp41 N-terminal
region have no impact on JR-FL Env-pseudovirus infectivity.
The modestly reduced total Env content of the mutant
pseudoviruses is therefore irrelevant to the infection process,
presumably because the content of functional trimers is
unchanged.shedding from pseudovirions. (A) Pseudovirions expressing the JR-FLWT or
ated, at either 4 °C or 37 °C. (B) The pseudovirions were incubated for 2 h at the
-pseudotyped virus served as a reference standard. The amount of virion-bound
°C (=100%).
Fig. 4. Effect of gp41 N-terminal substitutions on Env-pseudotyped virus
infectivity. Pseudovirions, containing normalized amounts of p24 antigen and
bearing the WT or mutant forms of JR-FL Env, were serially diluted and used to
infect U87.CD4.CCR5 cells. Infectivity was quantified by measuring luciferase
activity 4 days post infection.
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Env-mediated fusion
Despite the above conclusion, it still seemed possible that
the five gp41 substitutions could affect Env function, asFig. 5. Effect of gp41 N-terminal substitutions on Env-mediated cell–cell fusion. The
triangles) forms of JR-FL Env were determined in a β-lactamase reporter assay usin
and B) or low levels of both levels of CD4 and CCR5 (RC49 cells; panels C and D). T
by each Env (panels A and C), or of the maximal fusion mediated by the WT Env (pa
experiments. The various kinetic parameters are described in Table 2.assessed in a more direct assay of fusion. Some amino acid
changes in the gp41 HR1 region can impair fusion
efficiency and slow the kinetics of fusion (Reeves et al.,
2005). We therefore studied the kinetics of fusion mediated
by the WT and mutant Env glycoproteins using a β-
lactamase cell–cell fusion assay. Here, HeLa-CD4/CCR5
target cells were loaded with the fluorescent dye CCF2-AM
and mixed with effector cells expressing Env glycoproteins
and a β-lactamase-expressing plasmid. Cell–cell fusion that
leads to cytoplasm mixing allows cleavage of CCF2 by β-
lactamase and a fluorescence change that can be accurately
quantified in real time. Using this assay, we observed that in
JC53 cells, the rate and efficiency of fusion membrane
mediated by the WT and mutant Envs were similar (Figs.
5A and B; Table 2). However, when the experiment was
repeated using RC49 cells, membrane fusion mediated by
the mutant Env occurred slightly, but detectably, more
slowly than by the WT Env (Fig. 5C; Table 2), and the
maximum extent of fusion was reduced by ∼30% (Fig. 5D;
Table 2). The two HeLa-CD4/CCR5 cell lines differ in that
JC53 cells express much higher levels of CD4 and CCR5
than RC49 cells (Platt et al., 1998).
Overall, we conclude that the gp41 N-terminal sequence
changes have little effect on the fusion function of Env, although
a modest impairment is detectable when receptor levels are low,
as on RC49 cells.kinetics of cell–cell fusion mediated by the WT (black squares) and mutant (grey
g HeLa-CD4/CCR5 cells expressing either relatively high (JC53 cells; panels A
he extent of fusion is expressed as the percentage of the maximal fusion mediated
nels B and D). The data represent the mean±standard error of three independent
Table 2
Kinetic parameters of cell–cell fusion mediated by the WT and mutant JR-FL
Env-pseudotyped virions†
Target cells Envelope Ymax (% WT)
a t1/2 (min)
b b c
JC53 JR-FL WT 92.2±3.1 33±2 8±1.4
JC53 JR-FL gp41 NT 1–5 104.5±4.3 37±2 8±1.5
RC49 JR-FL WT 97.8±2.9 48±1 12±1
RC49 JR-FL gp41 NT 1–5 67.6±5.8 59±3 14±2.1
†The kinetic parameters were derived using a β-lactamase reporter assay (see
Fig. 5). Data derived from three independent experiments were fitted to the
equation Y=Ymax/{1+exp[− (t− t1/2) /b]}. The coefficients extracted from these
curves±standard errors of the mean are shown.
a Fusion expressed as percentage of the maximal fusion mediated by the WT
JR-FL Env.
b Time to half-maximal fusion (in minutes).
c Exponential rate constant.
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WT and gp41 mutant Env glycoproteins on pseudoviruses, and
correlations with infection–inhibition
Measurements of antibody binding to Env glycoproteins on
the surface of virions and Env-expressing cells are complicated
by the presence of non-functional forms of Env intermingled
with functional, native trimers (Moore et al., 2006; Poignard
et al., 2003). This heterogeneity of Env-binding sites for anti-
bodies renders it impossible to ensure that a binding event
involves a functional spike, and as only functional spikes are
relevant to infectivity neutralization, drawing meaningful cor-
relations between binding and neutralization events has proven
problematic at best, impossible at worst (Cavacini et al., 1999;
Fouts et al., 1997, 1998; Moore et al., 2006; Nyambi et al.,
1998; Poignard et al., 2003). The observation that the 5
substitutions in the N-terminus of gp41 reduce the abundance of
non-native Env forms (dimers and tetramers) present on virions
without affecting trimers suggested that it might be worthwhileFig. 6. Effect of gp41 N-terminal substitutions on the binding of MAbs to pseudoviri
the WT (black bars) or mutant (white bars) forms of JR-FL Env were tested in a virus
is recorded.to explore how various antibodies reacted with the mutant Env
proteins. Another reason to perform such a study was to
determine whether the gp41 substitutions affect the antigenic
structure of gp120, based on reports that other gp41 changes can
have such an effect (Back et al., 1993; Klasse et al., 1993; Park
and Quinnan, 1999; Park et al., 1998; Thali et al., 1994).
To measure MAb-Env interactions, we first employed a
widely used virion-binding assay of the type that generates
results which are highly misleading for judging neutralization
mechanisms (Moore et al., 2006; Poignard et al., 2003). There
was no difference between the WT and mutant JR-FL Env-
pseudotyped virions in the extent to which they bound the
neutralizing MAbs b12, 2G12, 2F5 and 4E10 or the CD4-IgG2
protein (Fig. 6). However, three non-neutralizing MAbs, b6 and
15e to the CD4BS on gp120 and PA1 to the V3 region captured
significantly fewer mutant pseudovirions than WT, as did the
neutralizing anti-V3 MAb F425-B4e8 (P≤0.05 for each,
Mann–Whitney U test, one-tailed) (Fig. 6). A modest, but not
significant, decrease in capture of the mutant pseudovirions was
also observed with another non-neutralizing anti-V3 MAb, 447-
52D (Fig. 6). An additional non-neutralizing MAb, A32 to the
gp120 C1–C4 region, bound minimally, but comparably, to
both pseudovirion preparations (Fig. 6). The non-neutralizing
MAb 17b captured both pseudovirion preparations weakly in
the absence of sCD4, but its binding was increased when sCD4
was also present, consistent with the known ability of CD4 to
induce the exposure of the 17b epitope on gp120 (Thali et al.,
1993). Of note was that the sCD4-induction of the 17b epitope
was significantly greater (P=0.04, Mann–Whitney U test, one-
tailed) on the mutant pseudovirions than on the WT (Fig. 6).
For comparison with the Env-binding data, and to further
assess whether the changes to gp41 affected the native structure
of the Env complex, we measured the sensitivities of the WT
and mutant JR-FL Env-pseudovirions to inhibition by MAbs
(and the CD4-IgG2 protein). U87.CD4.CCR5 cells served asons. Equal amounts (judged by p24 antigen content) of virions expressing either
capture assay. The amount of p24 antigen captured by each of the indicted MAbs
Table 3
Neutralization of pseudovirus infectivity by MAbs, CD4-IgG2 and T-20
JR-FL WT JR-FL gp41 NT 1–5
CD4-IgG2 0.82 0.74
b12 0.15 0.17
2G12 1.6 1.7
2F5 6.2 5.9
4E10 13.4 14.1
17b N50 N50
17b+sCD4 25.9 15.2
b6 N50 N50
15e N50 N50
A32 N50 N50
F425-B4e8 2.94 2.64
PA1 N50 N50
447-52D NDa NDa
T-20 24.2 11.5
The numbers recorded are mean IC50 values in μg/ml for the reagents indicated
(in nM for T-20). IC50 values that differ between the WT and mutant viruses are
highlighted in bold. aND: Not done. We were not able to procure enough of this
reagent for use in neutralization assays. However, MAb 447-52D has been
reported to lack potent neutralization activity (IC50=32.6 µg/ml) against JR-FL
Env-pseudotyped viruses in an assay of comparable design (Binley et al., 2004).
193A.K. Dey et al. / Virology 372 (2008) 187–200targets for infection. The four broadly neutralizing MAbs (b12,
2G12, 2F5 and 4E10) and CD4-IgG2 all inhibited infection of
the two pseudoviruses with comparable potencies, as did the
neutralizing anti-V3 MAb F425-B4e8 (Table 3), whereas fiveFig. 7. Cell surface expression of wild-type and gp41 mutant Env glycoproteins and t
biotinylated, avidin-precipitated and detected using MAb ARP3119. Cell surface-ex
mutant Env glycoproteins were stained with 10 µg/ml of biotinylatedMAbs, followed
determined using isotype controls and subtracted from experimental values. The MFI
performed in triplicates.MAbs b6, 15e, A32, PA1 and 17b that lack neutralizing activity
against HIV-1 JR-FL failed to inhibit infection by either
pseudovirus (Table 3). We were unable to test the V3 MAb 447-
52D for neutralization as it was not available in sufficient
quantities, but this MAb has been reported to lack strong
activity against JR-FL Env-pseudotyped viruses in a similar
assay (Binley et al., 2004). We noted, however, that in the
presence of sCD4, MAb 17b neutralized the mutant Env-
pseudotyped virions∼2-fold more efficiently than the WT virus
(IC50 values of 15 and 26 μg/ml, respectively) (Table 3). This
finding is consistent with the modestly increased binding of 17b
to the mutant pseudoviruses in the presence of sCD4 (Fig. 6),
and suggests that the gp41 substitutions do have a detectable
impact on either the conformation of the gp120 component of
the native Env complex, or how that complex changes
configuration after sCD4 binding. The effect of the gp41
changes must be modest, however, as there was no difference in
neutralization of the two pseudovirus preparations by any of the
other test MAbs (Table 3).
We also studied T-20 sensitivity in the same assay system,
because the five amino acid changes are located close to the
gp41 HR1 region, which is associated with T-20 resistance
(Carmona et al., 2005; Greenberg and Cammack, 2004). The
IC50 for T-20 against the WT Env-pseudotyped virus was 2-fold
greater than against the mutant, suggesting that one or more of
the 5 substitutions does modestly affect the binding or antiviral
activity of this peptide (Table 3).heir reactivity with CD4-IgG2 and MAbs. (A) Cell surface-expressed Envs were
pressed CD47 served as a loading control (lower panel). (B) The WT and gp41
by streptavidin-PE. Background fluorescence due to the secondary antibody was
values are shown as mean±standard deviation from a representative experiment
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cells expressing the WT and gp41 mutant Env glycoproteins
Various studies have shown that Env forms and antibody-
binding profiles are different on transfected cells than on
infectious virions, probably because over-expression affects
Env processing pathways (Herrera et al., 2003, 2005; Sattentau
and Moore, 1995; Si et al., 2001; York et al., 2001). We
therefore expressed the full-length WTand gp41 mutant Envs in
HEK 293T cells and studied the binding of various neutralizing
and non-neutralizing antibodies. As seen with the pseudovir-
ions, WT Env was expressed at ∼3-fold higher levels than the
gp41 mutant, both within the transfected cells (data not shown)
and on their surface (Fig. 7A).
We used flow cytometry to analyze antibody binding to the
surface of the Env-expressing cells (Fig. 7B). Each MAb was
tested at a saturating concentration of 10 μg/ml. In contrast to
what was observed with the pseudovirions, few if any
differences were detected between the WT and gp41 mutant
Envs. A slight decrease in PA1 binding to the mutant Env was
marginally significant (P=0.05, Mann–Whitney U test, one-
tailed). The differences between what we observe with the cell
surface binding assay compared to the pseudovirion capture
assay may reflect the greater diversity of Env forms that are
present on cells (Herrera et al., 2003, 2005; Pancera and Wyatt,
2005).
Discussion
When the HIV-1 envelope glycoproteins are expressed as
recombinant proteins, for use as vaccine antigens, for structural
studies, or for analysis of neutralization mechanisms, their
structural heterogeneity creates problems. Thus, preparations of
soluble gp140 proteins can, and often do, contain monomers,
dimers, trimers, tetramers and aggregates (Center et al., 2004;
Earl et al., 1994; Schulke et al., 2002; Staropoli et al., 2000),
and multiple forms of membrane-bound Env are present on
pseudovirions and on Env-expressing cells (Herrera et al., 2005;
Moore et al., 2006; Poignard et al., 2003). The degree to which
these problems arise from the over-expression of Env, or from
the use of non-lymphoid cells, is hard to judge; the Env content
of naturally produced viruses may be less diverse than what
arises in transfection-based systems. Nonetheless, transfection
systems are widely used experimentally, and the practical
production of Env vaccine candidates usually requires the use of
non-lymphoid cells. The development of ways to reduce the
extent of Env heterogeneity prior to purification of trimers is
therefore useful, since it is generally assumed that trimers best
mimic the native, virion-associated form of Env.
We previously described one of the genetic influences on the
formation of aberrant forms of Env — the identity of selected
residues near the N-terminus of gp41 (Dey et al., 2007). The
residues associated with increased trimer formation/stabiliza-
tion are much rarer in subtype B viruses, compared to those
from other subtypes, particularly subtype A, for reasons that we
have yet to understand. However, when the relevant residues are
inserted into subtype B viruses, they increase the formation and/or stability of trimers (Dey et al., 2007). Considering that most
vaccine-related studies with soluble gp140 proteins have been
carried out using subtype B sequences as templates, it seems
possible that the commonly observed Env instability might not
be as pronounced with proteins from other subtypes as it is with
subtype B (Dey et al., 2007; Jeffs et al., 2004). Additional
studies will be required to further address these issues.
We have studied the effect of these gp41 residues most
extensively with the prototypic subtype B primary isolate, JR-
FL, initially in the context of soluble gp140 proteins, now with
full-length gp160s that are the basic of infectious Env-
pseudoviruses. The principal reasons were two-fold: to
determine whether the gp41 substitutions adversely affect the
overall structure of Env, which could be problematic for vaccine
purposes; and to see whether the reduction in the formation of
aberrant forms of Env could beneficially influence previously
problematic analyses of the relationships between antibody
binding to Env and the neutralization of virus infectivity.
The introduction of the five gp41 changes into full-length
gp160 proteins reduced Env expression overall by∼2–4 fold in
different assays, implying that they have a modest effect on Env
production or degradation. However, all of that reduction was
accounted for by the presence of lesser amounts of Env dimers
and tetramers; the trimer content was unchanged. The most
likely explanation of this effect is that the trimers are more
stable, so do not dissociate as readily into dimers and monomers
(the tetramers are probably dimers of dimers). This is spec-
ulation, however, and there may be other explanations. The
presence of a significant amount of gp120/gp41 monomers on
virus-like particles (VLPs) bearing JR-FL Env has been
reported (Moore et al., 2006); indeed, in that study, monomers
were the principal ‘non-functional’ Env form present, and they
were immunogenic when the VLPs were administered to
guinea-pigs (Crooks et al., 2007). We have not observed
significant amounts of Env monomers on pseudovirions.
Besides the obvious points that pseudovirions are not VLPs, it
should also be noted that the VLPs made by Moore et al. are
based on a cytoplasmic-tail truncated version of JR-FL gp160
(gp160ΔCT), whereas we used full-length gp160 to make the
pseudovirions. Cytoplasmic-tail truncation enhances cell sur-
face Env expression and incorporation into VLPs and virions,
but it is also known to affect the conformation of the external
domains of the Env complex (Akari et al., 2000; Edwards et al.,
2002; Kalia et al., 2003; Murakami and Freed, 2000; Piller
et al., 2000). Hence it is possible that gp160ΔCT trimers might
dissociate into monomers more readily than full-length trimers,
something that could be tested experimentally in the VLP
system.
The gp41 changes had no effect on pseudovirion infectivity,
and they did not cause any destabilization of the gp120–gp41
linkage. Thus, they seem benign from the perspective of the
overall topology of the Env complex. Their lack of effect on the
overall structure of functional, native Env complexes is further
shown by the similar binding of various neutralizing MAbs to
both the WT and mutant pseudovirions, and their identical
neutralization sensitivities. An exception was, however, the
slightly greater sensitivity of the mutant viruses to the CD4i
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comparable increase in 17b binding in a pseudovirion-capture
assay in the presence of sCD4. Presumably, the gp41 sub-
stitutions do have a modest impact on the exposure of the CD4i
epitope post CD4 binding. Broadly similar effects of selected
gp41 sequence changes on gp120 topology have been described
previously (Back et al., 1993; Klasse et al., 1993; Reitz et al.,
1988; Thali et al., 1994).
The gp41 sequence changes had a minor effect on the
kinetics of Env-mediated fusion in a cell–cell fusion assay that
was detectable only when CD4 and CCR5 levels were
relatively low (RC49 cells). This modest impairment of fusion
function is presumably too little to affect infectivity when the
same Env proteins are present on pseudovirions. Mutational
studies of the gp41 HR1 segment have shown that mutations
in the “a” and “d” positions, particularly helix-disrupting
mutations, impair fusion (Cao et al., 1993; Chen, 1994; Chen
et al., 1993; Dubay et al., 1992). The S553, K567 and R588
residues that we have focused on are not helix disrupting and
occupy the “b” position in the coiled-coil helix, which may
explain why their adverse effect is so modest. The substitu-
tions also had a slight effect on T-20 sensitivity, decreasing the
IC50 by 2-fold. Although the substitutions lie outside the
547GIV549 ‘hot spot’ associated with T-20 reactivity (Rimsky
et al., 1998), natural polymorphisms at position 553 (N553S),
most commonly observed in non-subtype B isolates, have
been associated with increased susceptibility to T-20, as have
reductions in the rate of fusion that arise due to prolonged
exposure of the T-20 binding site (Carmona et al., 2005;
Whitcomb et al., 2003).
Studies of antibody binding to pseudovirions showed that
several non-neutralizing MAbs (b6, 15e, F425-B4e8 and PA1)
to CD4BS and V3 epitopes bound to the mutant Env
significantly (2–3 fold) less than to the WT. The differential
binding was not seen, however, with two other MAbs that also
lack neutralizing capacity against JR-FL, 447-52D and A32.
The decreased binding of the non-neutralizing MAbs to
pseudoviruses bearing the mutant Env could be due to the
lesser content of non-trimeric (i.e., non-functional) Env forms
present. This explanation would be consistent with an earlier
report (Poignard et al., 2003). It was notable that when the
pseudovirion binding (Fig. 6) and neutralization (Table 3) data
were compared, there was no clear relationship between the
ability of a MAb to capture pseudoviruses and impair their
infectivity, as reported previously (Moore et al., 2006; Poignard
et al., 2003). Thus some neutralizing MAbs captured pseudo-
viruses strongly (b12, 2G12, F425-B4e8), but others did not
(2F5, 4E10). And all three V3 MAbs (PA1, 447-52D and F425-
B4e8) captured pseudoviruses efficiently, but only F425-B4e8
was neutralizing. Nonetheless, the introduction of the 5
substitutions in gp41 that reduce (but do not eliminate) the
presence of non-native forms of Env on pseudoviruses did
improve the performance of the virion capture assay. For
example, the differential between the closely related neutraliz-
ing and non-neutralizing CD4BS MAbs b12 and b6 was
substantially increased in the virion capture assay when the
gp41 mutant pseudoviruses were used (Fig. 6).Binding assays involving Env expressed on the surface of
transfected cells were less informative, probably because of the
multiplicity of Env configurations present on the cells. This
further reinforces the problems associated with assays of this
type when they are used to assess the relationship between
antibody binding and virus-neutralization (Gorse et al., 1999;
Herrera et al., 2003; Sattentau and Moore, 1995; Si et al., 2001;
York et al., 2001).
Overall, we conclude that the five amino acid changes in
gp41 have a generally beneficial effect on the overall con-
figuration of the subtype B gp140 and gp160 Env proteins, by
reducing the presence of non-native Env forms without
compromising the function of trimers. The use of this strategy
should therefore facilitate the production of Env trimers for
structural and immunogenicity studies.
Materials and methods
Plasmids and DNA mutagenesis
The pCI plasmid was used to express full-length WT JR-FL
(gp160) Env (JR-FLWT) (Herrera et al., 2005). The JR-FL gp41
NT 1–5 mutant was created by site-directed DNA mutagenesis;
five amino acid substitutions (M535I, L543Q, N553S, Q567K
and G588R) near the N-terminus of gp41 were made using the
QuikChange® II XL site-directed mutagenesis kit (Stratagene
Inc., CA) and the appropriate primers. The introduced mutations
were verified by sequencing. The pcDNA3.1-Furin plasmid was
used for expressing Furin (Binley et al., 2000).
Antibodies and cell lines
Soluble CD4, CD4-IgG2 (PRO 542) (Allaway et al., 1995)
and the anti-V3 (JR-FL) MAb PA1 (Trkola et al., 1996a) were
provided by Dr. William Olson (Progenics Pharmaceuticals,
NY). MAb CA13 (ARP3119) to a linear epitope in the gp120
C1 region, from Ms C. Arnold, was provided by the EU
Programme EVA Centralized Facility for AIDS Reagents,
NIBSC, UK (AVIP Contract Number LSHP-CT-2004-503487).
MAbs 2G12 (Buchacher et al., 1994; Scanlan et al., 2002;
Trkola et al., 1996b), 2F5 (Buchacher et al., 1992; Muster et al.,
1993) and 4E10 (Buchacher et al., 1992; Stiegler et al., 2001;
Zwick et al., 2001) were obtained from Hermann Katinger,
MAb 17b (Thali et al., 1993) from James Robinson and MAb
b12 (Burton et al., 1991) from Dennis Burton. MAbs A32
(Moore et al., 1994; Wyatt et al., 1995) and 15e (Robinson et al.,
1990) were obtained from the Neutralizing-Antibody Consor-
tium (NAC) repository. F425-B4e8 (Cavacini et al., 2003) was
obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH, from Dr.
Marshall Posner and Dr. Lisa Cavacini. The anti-V3 MAb 447-
52D was also obtained from the NIH AIDS Research and
Reference Reagent Program, NIAID, NIH, contributed by S.
Zolla-Pazner (Gorny et al., 1992, 1993). T-20 (Enfuvirtide)
(Wild et al., 1994) was a gift from Roche Laboratories Inc., NJ.
All cell lines were maintained at 37 °C in an atmosphere
containing 5% CO2. Human Embryonic Kidney (HEK) 293T
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(DMEM, GIBCO), containing 10% fetal calf serum (FCS),
2 mM L-glutamine, antibiotics (100 U/ml penicillin, 100 μg/ml
streptomycin), and 0.5 mg/ml of the neomycin analog G-418.
U87.CD4.CCR5 and U87.CD4.CXCR4 cells (provided by Dan
Littman) were cultured under similar conditions to the HEK
293T cells but under selection by 0.3 mg/ml of G-418 and
0.5 μg/ml of puromycin.
Transfection conditions for pseudovirus production and
purification
To produce luciferase-expressing, Env-pseudotyped viruses,
1×108 HEK 293T cells in growth media lacking antibiotics
were co-transfected with plasmid DNA expressing gp160 Envs
(WT or gp41 mutant) and the pNL4-3Env(−)Luc(+) reporter
plasmid (Connor et al., 1995, 1996), using Polyethylenimine
(PEI) (Polysciences Inc., Warrington, PA) (Boussif et al., 1995;
Kirschner et al., 2006). Sixteen hours later, the cells were
washed and the medium was replaced with DMEM containing
10% FCS, antibiotics and L-glutamine. Forty-eight hours post-
transfection, the virion-containing supernatants were clarified
by low speed centrifugation and filtered through a 0.45-μm
membrane. The clarified, filtered supernatants were layered
over a 20% sucrose cushion in phosphate-buffered saline, and
centrifuged for 2 h at 100,000 ×g, 4 °C. The viral pellet was then
re-suspended in either PBS (for all biochemical analysis) or
DMEM (for viral infectivity assay and neutralization assays).
For studying cell surface expression of JR-FL Env, 5×106
HEK 293T cells were transiently transfected with plasmid DNA
essentially as described above. pcDNA3.1-Furin was used for
Furin co-transfection at a Furin:Env plasmid DNA ratio of 2:1
(Binley et al., 2000). Twenty-four hours later the cells were
washed and fresh culture media was added. Forty-eight hours
post-transfection, the cell surface-expressed Envs were biotin-
labeled for polyacrylamide gel electrophoresis or stained with
anti-Env antibodies for FACS analysis, as described below.
Biotinylation of cell surface-expressed Env
Forty-eight hours post-transfection (as above), the surface-
expressed envelope glycoproteins were biotinylated as de-
scribed previously (Daniels and Amara, 1998) with minor
modifications. Briefly, the Env-expressing cells were washed
extensively with ice-cold PBS containing 1.2 mM CaCl2, 1 mM
MgCl2 and incubated with 0.5 mg/ml of EZ-link sulfo-NHS-SS-
Biotin (Pierce Biotechnology, Rockford, IL), for 1 h at 4 °C.
The biotin reaction was quenched using 50 mM ammonium
chloride. The cells were then washed extensively and lysed in a
buffer containing 25 mM Tris–HCl (pH 8.0), 150 mM NaCl,
1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride
(PMSF), and 1× Protease Inhibitors cocktail (Roche Diagnostic
GmbH, Mannheim, Germany). The homogenates were centri-
fuged at 14,000 ×g for 15 min at 4 °C. A 50 μl aliquot of the
supernatants was removed to measure total protein levels and to
analyze the Env content; the remaining supernatant was
incubated with 50 μl of NeutrAvidin agarose resin (Pierce) for2 h at 4 °C, to precipitate biotin-labeled proteins. The pellets
were then washed thrice in TSA buffer, once in 20 mM Tris–
HCl (pH 8.0), 500 mM NaCl, and finally in 50 mM Tris–HCl
(pH 8.0). Bound proteins were re-suspended in 50 μl of 2× SDS
sample buffer, boiled and resolved on a reduced SDS-PAGE
gradient (4–12%) Tris–glycine gel (Invitrogen, Carlsbad, CA).
After transfer to a PVDF membrane, the samples were
immunoblotted with anti-gp120 ARP3119 (see above), anti-
CD47 (Santa Cruz Biotechnology; at 0.31 μg/ml) or anti-
GAPDH (Meridian Life Science, Inc.; at 0.1 μg/ml) antibodies.
GAPDH was used to control for equal loading of proteins in the
total cell lysate (data not shown), cell surface CD47 expression
served a similar purpose when studying surface-expressed Env.
Fluorescence-activated cell sorting (FACS) assay for MAb
binding to cell surface Env
CD4-IgG2 and MAbs were biotinylated using the EZ-link
Sulfo-NHS-LC-Biotinylation kit (Pierce), according to the
manufacturer’s instructions. Env-expressing, transiently trans-
fected HEK 293T cells (0.5×106 cells per analysis) were
harvested, extensively washed with PBS and incubated with
10 μg/ml of biotinylated CD4-IgG2 or MAbs in FACS buffer
(PBS containing 5% FCS), for 1 h at 4 °C. The cells were
washed repeatedly in FACS buffer and then incubated with
100 μl of Streptavidin-phycoerythrin (PE) (BD Biosciences), at
a 1:250 dilution, for 30 min at 4 °C. The stained cells were then
washed, fixed using 2% paraformaldehyde, and analyzed. Each
binding assay was performed in triplicate. Mean Fluorescence
Intensity (MFI) values were derived using the appropriate
isotype control MAb, the resulting background signal being
subtracted from the experimental results and presented as
mean±standard deviation.
BN-PAGE, SDS-PAGE and western blotting
Env expressed on the surface of pseudovirions was analyzed
under non-denaturing conditions by the use of BN-PAGE
(Schulke et al., 2002) with the modifications described
elsewhere (Moore et al., 2006; Schagger et al., 1994). To
release Env glycoproteins from the pseudovirion surface, an
equal volume of solubilization buffer (0.12% Triton X-100 in
1 mM EDTA/1.5 M aminocaproic acid) and 5 μl of a protease
inhibitor cocktail (Sigma) were added, followed by an equal
volume of double-strength sample buffer (100 mM morpholi-
nepropanesulfonic acid (MOPS), 100 mM Tris–HCl, pH 7.7,
40% glycerol, 0.1% Coomassie blue). The extracts were then
loaded onto a 4–12% Bis–Tris NuPAGE gel (Invitrogen) and
electrophoresed at 4 °C for 3 h at 100 V. The cathode buffer was
50 mM MOPS/50 mM Tris, pH 7.7, containing 0.002%
Coomassie blue, and the same buffer without Coomassie blue
served as the anode buffer. The gel was then blotted onto a
polyvinylidene difluoride (PVDF) membrane, which was then
washed with 30% methanol/10% acetic acid followed by 100%
methanol to remove excess Coomassie blue dye. Thyroglobulin
(669 kDa), Ferritin (440 kDa), Catalase (232 kDa), Lactate
dehydrogenase (140 kDa) and BSA (66 kDa) were used as
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Densitometric analyses were performed using ImageJ software
(NIH).
SDS-PAGE analysis of denatured Env glycoproteins was
performed as described previously (Schulke et al., 2002). The
pseudovirions were lysed by boiling in Laemmli sample buffer
(62.5 mM Tris–HCl [pH 6.8], 25% glycerol, 2% SDS, 0.1%
bromophenol blue, 10% 2-mercaptoethanol) in the presence of
50 mMDTT, and then fractionated using either a 4–12% or a 8–
16% gel. Overnight blotting onto a PVDF membrane was
performed as described previously (Schulke et al., 2002). The
membrane was then de-stained, treated with blocking buffer
(4% nonfat milk in PBS) for 1 h and probed using 0.5 μg/ml of
the anti-gp120 MAb CA13 or 20 μg/ml each of 4E10 and 2F5
(anti-gp41 MAb cocktail). The mouse MAb 39/6.14 (Abcam
Inc., MA) was used to detect p24. Horseradish peroxidase-
labeled anti-mouse (1:5000) or anti-human (1:2000) immuno-
globulin G (IgG) were used, as appropriate, to detect the
primary MAbs, followed by the Western Blot Chemilumines-
cence Reagent Plus system (Perkin-Elmer Life Sciences, MA).
The MultiMark® multi-colored standard kit (Invitrogen, CA)
was used as a molecular weight marker.
Assay for gp120 dissociation from pseudovirions
Pseudovirions, in 200 μl of PBS containing 0.5% BSA, were
incubated with or without sCD4 for 2 h at 4 °C or 37 °C (or
without sCD4 but at various temperatures), then layered over a
1 ml cushion of 20% sucrose and ultra-centrifuged at 100,000 g
for 1.2 h, 4 °C. The purified virions were then re-suspended in
200 μL of dilution buffer [TMSS: 2% milk powder, 20% sheep
serum in Tris–buffered Saline (TBS)] for analysis of their
gp120 content by capture ELISA.
gp120 capture ELISA
This assay was carried out as previously described (Moore et
al., 1992). Briefly, gp120 was captured onto microtiter plate
wells by the absorbed sheep antibody D7324 to the C-terminus
(Cliniqa Corp.), and detected using either polyclonal HIVIG or
CD4-IgG2 (0.1 μg/ml).
Virus capture assay
Virus capture assay was performed as previously described
(Poignard et al., 2003). Briefly, ELISA plates were coated with
goat anti-human or goat anti-mouse IgG (Fc-specific) antibody
(Sigma, MO), blocked with 3% BSA in PBS, then incubated
with anti-gp120 MAbs at 10 μg/ml in 100 μl of PBS. After
thorough washing to remove unbound MAbs, 100 μl of medium
containing pseudoviruses (0.5–1.5 ng of p24 antigen) was
added for 4 h at room temperature. After thorough washing, the
captured viruses were then lysed in 200 μl of lysis buffer and
their p24 antigen content determined using a HIV-1 p24 ELISA
kit (ZeptoMetrix Corp., NY). Wells lacking anti-gp120
antibody served as negative controls for background binding
of the added pseudoviruses.Infectivity and neutralization assays
Pseudotyped virions bearing JR-FL envelope glycoproteins
(WT and mutant) were produced by co-transfection of selected
env clones with a luciferase-expressing reporter vector, pNL4-
3Env(−)Luc(+), as described above. To measure infectivity,
luciferase-expressing Env-pseudotyped viruses (50 μl) contain-
ing normalized amounts of p24 antigen were added to 3×103
U87.CD4.CCR5 cells/well (U87.CD4.CXCR4 cells were used
as a negative control). Four days later, the cells were lysed with
75 μl of 1×Glo lysis buffer (Promega, CA), for subsequent
quantification of luciferase, expressed by the Env-pseudotyped
virions that has the gene for firefly luciferase inserted into the
nef gene, using the Bright-Glo™ Luciferase Assay Substrate
(Promega, CA) and a VICTOR3 1420 multilabel counter
(Perkin-Elmer Life Sciences, MA).
Neutralization of infectivity was performed as described
previously (Trkola et al., 1998). The pseudovirions were
incubated with an equal volume of various MAbs, CD4-IgG2
or T-20 for 1 h at 37 °C before determination of the residual
infectivity using U87.CD4.CCR5 cells, as outlined above. The
concentration of each inhibitor was expressed as that present
after the inhibitor–virus mixture was added to the cells. The
data were analyzed by non-linear regression (variable-slope
sigmoidal dose response) to calculate the inhibitor concentra-
tions that caused 50% reductions in luciferase expression (IC50),
using GraphPad Prism 4 software (maximal viral production in
absence of inhibitor was designated as 100%).
Cell–cell fusion assay
The β-lactamase cell–cell fusion assay was performed in
HeLa-CD4/CCR5 cells (JC53 and RC49), as described
previously (Lineberger et al., 2002; Rucker et al., 1997). JC53
cells express higher levels of both CD4 and CCR5 than RC49
cells (Platt et al., 1998).
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